Pulmatrix is on the Cruelty Free Investing list for exploiting animals because the company does animal testing in developing and commercializing of some of their therapeutic products.
The company stated in the following report that they conduct pre-clinical trials of their drugs on animals.
“One or more of our product candidates may fail to meet safety and efficacy standards in human testing, even if those product candidates are found to be effective in animal studies.” (Page 17) Read the full document
Pulmatrix, Inc. is a clinical stage biotechnology company, which is focused on the discovery and development of novel inhaled therapeutic products intended to prevent and treat respiratory diseases and infections with significant unmet medical needs. It designs and develops inhaled therapeutic products based on its proprietary dry powder delivery technology, iSPERSE, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. The company was founded by David Edwards, Mark Gabrielson, Alexander Klibanov, and Robert Langer in 2013 and is headquartered in Lexington, MA. [Source: MarketWatch]
Company Website: http://pulmatrix.com